Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • De Vries, TI
  • Eikelboom, John
  • Bosch, Jackie
  • Westerink, J
  • Dorresteijn, JAN
  • Alings, M
  • Dyal, L
  • Berkowitz, SD
  • Van der Graaf, Y
  • Fox, KAA
  • Visseren, FLJ

publication date

  • October 1, 2019